ARK Investment Management LLC Cuts Stake in ARK Genomic Revolution ETF (BATS:ARKG)

ARK Investment Management LLC lessened its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 9.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,340 shares of the company’s stock after selling 777 shares during the quarter. ARK Investment Management LLC’s holdings in ARK Genomic Revolution ETF were worth $172,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC bought a new position in shares of ARK Genomic Revolution ETF during the first quarter valued at approximately $49,000. Park Avenue Securities LLC raised its stake in ARK Genomic Revolution ETF by 14.0% during the first quarter. Park Avenue Securities LLC now owns 11,667 shares of the company’s stock valued at $336,000 after buying an additional 1,435 shares during the last quarter. Hilltop Holdings Inc. raised its stake in ARK Genomic Revolution ETF by 6.0% during the fourth quarter. Hilltop Holdings Inc. now owns 7,652 shares of the company’s stock valued at $251,000 after buying an additional 433 shares during the last quarter. Principal Securities Inc. bought a new stake in ARK Genomic Revolution ETF in the fourth quarter worth $32,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of ARK Genomic Revolution ETF by 271.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 642,800 shares of the company’s stock worth $21,090,000 after acquiring an additional 469,740 shares during the last quarter.

ARK Genomic Revolution ETF Stock Performance

ARK Genomic Revolution ETF stock traded up $0.01 during trading hours on Tuesday, hitting $26.98. The stock had a trading volume of 1,048,945 shares. The stock has a 50-day simple moving average of $25.10 and a 200-day simple moving average of $26.47.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.